Ramazan YOLAÇAN, Ercan YİĞİT, Ümit KARABULUT, Ali ÜZEL, Feyzullah UÇMAK, Muhsin KAYA

Pankreas Kanseri Tanılı Hastalarımızda Prognostik Faktörlerin İncelenmesi

Amaç: Pankreas kanseri oldukça kötü prognozlu bir hastalık olup, insidansı giderek artmaktadır. Bu hastalıkta birden fazla prognostik belirteç bulunmaktadır. Bu çalışmadaki amaç kliniğimizde pankreas kanseri tanısı alan hastaların yaşam süresini etkileyen prognostik faktörleri saptamaktı. Yöntemler: Kliniğimize Ocak 2011-Haziran 2020 tarihleri arasında başvuran ve pankreas kanseri tanısı konulan 127 hastanın demografik ve klinik özellikleri, laboratuvar sonuçları, kontrastlı abdomen tomografisi bulguları ve tedavilere cevapları retrospektif olarak değerlendirildi. Bulgular: Hastaların 85’i (%67) erkek 42’si (%33) kadın olup, yaş ortalaması 62,6±12,5 (27-90) yıl, ortalama sağ kalma süresi 11,6±1,3 ay; 1 yıllık ortalama sağ kalım oranı %31 ve 5 yıllık ortalama sağ kalım oranı %0,9 idi. Pankreas kanseri prognozu ile cinsiyet, tümör çapı, tümör lokalizasyonu, DM varlığı, patolojik LAP varlığı, vasküler invazyon, kemoterapi alınması, serum CA 19-9 ve CA125 seviyesi arasında anlamlı ilişki saptanmazken, ileri yaş (p=0.01), karaciğer metastazı (P=0.016) ve yüksek serum CEA düzeyinin (p=0.013) kötü prognostik faktör ve cerrahi rezeksiyon yapılmasının (p=0.039) iyi prognostik faktör olduğu saptandı. Sonuç: Pankreas kanseri tedavisi sırasında hastalığın prognozunu etkileyen faktörlerin göz önünde bulundurulması faydalı olabilir.

Anahtar Kelimeler:

Pankreas kanseri, Tümör markırları, Prognostik faktörler

The Measurement of Neutrophil Gelatinase Associated Lipocalin in Umbilical Cord Blood and the Assessment of Its Relationship with Neonatal Results

Objectives: In this study, the relationship of cord blood Neutrophil Gelatinase-Associated Lipocalin (NGAL) with neonatal diseases was investigated. Methods: NGAL levels were measured in the cord blood of 180 babies born between 2015 and 2016. Patients were classified according to maternal diseases, neonatal diseases and demographic characteristics. Obtained data were compared with cord blood NGAL levels. Results: In our study, the mean NGAL levels were 1283.99 ng/mL in boys and 1306.52 ng/mL in girls. Umbilical cord blood NGAL levels of infants diagnosed with intrauterine growth retardation (1913.4±2833.5 ng/mL) and prolonged premature rupture of membranes (2594.2±2037.1 ng/mL) were found to be statistically high (p0.05). Conclusions: Neutrophil Gelatinase-Associated Lipocalin, may be useful as a diagnostic biomarker in the evaluation of maternal and neonatal diseases. However, studies on larger patient populations are needed.

Keywords:

Neutrophil Gelatinase Associated Lipocalin, umbilical cord blood, newborn,

PDF

___

1. Haddock G. Carter DC. Aetiologyof pancreatic cancer. Br J Surg 1990; 77: 1159-66.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. Jan; 60: 277–300.
3. M. Gultekin, G. Boztas, E. Utku Simsek, ve ark. 2013 yılı Türkiye Kanser İstatistikleri. Ankara; 2016.
4. Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008 Jan; 10: 371–6.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. Jan; 59: 225–49.
6. Wang H, Liu J, Xia G, et al. Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. Sci Rep. 2020; 10:7048. 10.1038/s41598-020- 64068-3.
7. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013 Sep; 63: 318-48.
8. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996 Oct 28; 156: 2255– 60.
9. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of metaanalytical studies. Int J Epidemiol. 2015 Feb; 44: 186–98.
10. Fernandez E, La Vecchia C, Decarli A, Attributable risks for pancreatic cancer in nothern Italy. Cancer Epidemiol Biomarkers prev. 1996; 5; 23-27.
11. Rashleigh-Belcher HJ, Russell RC, Lees WR. Cutaneous seeding of pancreatic carcinoma by fineneedle aspiration biopsy. Br J Radiol. 1986 Feb;59(698):182–3.
12. Margeret A. Tempero, Mokenge P. Malafa, Horacio Asbun, Stephen W. Behrman, Al B. Benson CC. Pancreatic Adenocarcinoma. 2. 2015.
13. Al-Haddad M, Martin JK, Nguyen J, et al. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg. 2007 Sep; 11: 1168–74.
14. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985 Aug; 120: 899–903.
15. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18; 350: 1200–10.
16. Yang R, Cheung MC, Byrne MM, et al. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Arch Surg. 2010 Jan; 145: 49–56.
17. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17; 297: 267–77.
18. Bernhard J, Dietrich D, Scheithauer W, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-- SAKK 44/00- CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug 1; 26: 3695–701.
19. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20; 27: 5513–8.
20. Howlader N, Noone AM, Krapcho M, et al. Cancer Statistics Review, 1975-2012 - SEER Statistics. National Cancer Institute. Bethesda, MD.
21. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British journal of cancer. 2005; 92: 2076–83.
22. Chari ST, Leibson CL, Rabe KG, Ransom J, de AM, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005; 129: 504–11.
23. Yamamoto T, Yagi S, Kinoshita H, et al. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol. 2015 Jan 7; 21: 262-8. doi: 10.3748/wjg.v21.i1.262.
24. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas -616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567- 79.
25. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg 1995;221:133-48.
26. Uçar G, Ergün Y, Açıkgöz Y, ve ark. Opere Pankreas Adenokanserli Hastalarda Kemoterapiye Kemoradyoterapi Eklemenin Katkısı. Dicle Tıp Dergisi / Dicle Med J (2020) 47: 897-902.
27. Helvacı K, Üyetürk Ü, Sönmez Ö et al. Evaluation Of Demographic And Clinicopathological Characteristics Of Pancreatic Adenocarcinoma Patients. Acta Oncol Turc2016; 49: 91-101.
28. Garcea G, Dennison AR, Pattenden CJ, et al. (2008) Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 9: 99-132.
29. Lianyuan T, Deyu L, Haibo Y, Yadong D, Guanjing T. Clinical features and prognostic factors of elderly patients with metastatic pancreatic cancer: a population-based study. Aging (Albany NY). 2021 Feb 26; 13: 7133-46.
30. W. Hartwig, O. Strobel, U. Hinz, et al. Werner CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy Ann. Surg. Oncol., 20 (7) (2013), pp. 2188- 96.
31. Gu YL, Lan Ch, Pei H, et al. Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. Asian Pac J Cancer Prev. 2015; 16: 6569–73..
32. Nurmi AM, Mustonen HK, Stenman UH, Seppänen HE, Haglund CH. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma. Sci Rep. 2021; 11: 781.